RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shenzhen Lachesis mHealth raised $29 million in a B Round led by GTLA to develop its smart healthcare and mobile health technologies. The company’s major product is the Intelligent Hospital Ward System, a medical device that includes a diagnosis and treatment assistant, wireless monitoring and other services to improve patient care. Lachesis’s product targets the post-acute-care market in general hospitals.
Source: China Biotoday
